{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:49:37Z","timestamp":1753890577958,"version":"3.41.2"},"reference-count":120,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004431","name":"Fondation de France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004431","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Heart failure (HF) and cancer are responsible for 50% of all deaths in middle-aged people. These diseases are tightly linked, which is supported by recent epidemiological studies and case control studies, demonstrating that HF patients have a higher risk to develop cancer such as lung and breast cancer. For HF patients, a one-size-fits-all clinical management strategy is not effective and patient management represents a major economical and clinical burden. Anti-cancer treatments-mediated cardiotoxicity, leading to HF have been extensively studied. However, recent studies showed that even before the initiation of cancer therapy, cancer patients presented impairments in the cardiovascular functions and exercise capacity. Thus, the optimal cardioprotective and surveillance strategies should be applied to cancer patients with pre-existing HF. Recently, preclinical studies addressed the hypothesis that there is bilateral interaction between cardiac injury and cancer development. Understanding of molecular mechanisms of HF-cancer interaction can define the profiles of bilateral signaling networks, and identify the disease-specific biomarkers and possibly therapeutic targets. Here we discuss the shared pathological events, and some treatments of cancer- and HF-mediated risk incidence. Finally, we address the evidences on bilateral connection between cardiac injury (HF and early cardiac remodeling) and cancer through secreted factors (secretoms).<\/jats:p>","DOI":"10.3389\/fcvm.2022.929259","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T05:29:37Z","timestamp":1657862977000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Evidence for reciprocal network interactions between injured hearts and cancer"],"prefix":"10.3389","volume":"9","author":[{"given":"Melisa N.","family":"Guler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie M.","family":"Tscheiller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Sabater-Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan R.","family":"Gimeno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Canan G.","family":"Nebigil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1093\/cvr\/cvz035","article-title":"Common risk factors for heart failure and cancer.","volume":"115","author":"Meijers","year":"2019","journal-title":"Cardiovasc Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1113\/JP276746","article-title":"Mechanisms underlying the cross-talk between heart and cancer.","volume":"598","author":"Brancaccio","year":"2020","journal-title":"J Physiol."},{"key":"B3","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/ejhf.1539","article-title":"Cancer and heart disease: associations and relations.","volume":"21","author":"de Boer","year":"2019","journal-title":"Eur J Heart Fail."},{"key":"B4","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1161\/CIRCULATIONAHA.118.038481","article-title":"Response by meijers and de boer to letters regarding article, \u201cheart failure stimulates tumor growth by circulating factors\u201d.","volume":"139","author":"Meijers","year":"2019","journal-title":"Circulation."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1001\/jama.2019.17415","article-title":"Need for multidisciplinary research and data-driven guidelines for the cardiovascular care of patients with cancer.","volume":"322","author":"Meijers","year":"2019","journal-title":"JAMA."},{"key":"B6","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/ejhf.472","article-title":"Incidence of cancer in patients with chronic heart failure: a long-term follow-up study.","volume":"18","author":"Banke","year":"2016","journal-title":"Eur J Heart Fail."},{"key":"B7","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1038\/hr.2017.45","article-title":"Does the pathophysiology of heart failure prime the incidence of cancer?","volume":"40","author":"Sakamoto","year":"2017","journal-title":"Hypertens Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jjcc.2020.07.026","article-title":"Differential risk of incident cancer in patients with heart failure: a nationwide population-based cohort study.","volume":"77","author":"Kwak","year":"2021","journal-title":"J Cardiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jacc.2016.04.053","article-title":"Heart failure after myocardial infarction is associated with increased risk of cancer.","volume":"68","author":"Hasin","year":"2016","journal-title":"J Am Coll Cardiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/ejhf.1165","article-title":"Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge.","volume":"20","author":"Ameri","year":"2018","journal-title":"Eur J Heart Fail."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2020.598384","article-title":"Development of cancer in patients with heart failure: how systemic inflammation can lay the groundwork.","volume":"7","author":"Ausoni","year":"2020","journal-title":"Front Cardiovasc Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/ehf2.12184","article-title":"Cardiac muscle wasting in individuals with cancer cachexia.","volume":"4","author":"Barkhudaryan","year":"2017","journal-title":"ESC Heart Fail."},{"key":"B13","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","article-title":"Risk of arterial thromboembolism in patients with cancer.","volume":"70","author":"Navi","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15639-5","article-title":"Fatal heart disease among cancer patients.","volume":"11","author":"Stoltzfus","year":"2020","journal-title":"Nat Commun."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.mayocp.2014.05.013","article-title":"Evaluation and management of patients with heart disease and cancer: cardio-oncology.","volume":"89","author":"Herrmann","year":"2014","journal-title":"Mayo Clin Proc."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1002\/cncr.27968","article-title":"Assessing the utility of cancer-registry-processed cause of death in calculating cancer-specific survival.","volume":"119","author":"Hu","year":"2013","journal-title":"Cancer."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","article-title":"A population-based study of cardiovascular disease mortality risk in US cancer patients.","volume":"40","author":"Sturgeon","year":"2019","journal-title":"Eur Heart J."},{"key":"B18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s10654-017-0231-5","article-title":"Myocardial infarction and future risk of cancer in the general population-the Tromso Study.","volume":"32","author":"Rinde","year":"2017","journal-title":"Eur J Epidemiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1172\/JCI0215380","article-title":"Mixed signals in heart failure: cancer rules.","volume":"109","author":"Hoshijima","year":"2002","journal-title":"J Clin Invest."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013754","article-title":"Reverse cardio-oncology: cancer development in patients with cardiovascular disease.","volume":"9","author":"Aboumsallem","year":"2020","journal-title":"J Am Heart Assoc."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1002\/ejhf.2029","article-title":"Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).","volume":"22","author":"de Boer","year":"2020","journal-title":"Eur J Heart Fail."},{"key":"B22","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.molcel.2014.03.030","article-title":"Stress, inflammation, and defense of homeostasis.","volume":"54","author":"Chovatiya","year":"2014","journal-title":"Mol Cell."},{"key":"B23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1146\/annurev.physiol.65.092101.142249","article-title":"Stress-activated cytokines and the heart: from adaptation to maladaptation.","volume":"65","author":"Mann","year":"2003","journal-title":"Annu Rev Physiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"E382","DOI":"10.1503\/cmaj.161033","article-title":"Inflammation, cardiovascular disease and cancer: moving toward predictive medicine.","volume":"189","author":"Ridker","year":"2017","journal-title":"CMAJ."},{"key":"B25","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1093\/eurheartj\/eht367","article-title":"Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis.","volume":"35","author":"Kaptoge","year":"2014","journal-title":"Eur Heart J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer.","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell."},{"key":"B27","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","article-title":"Harnessing cytokines and chemokines for cancer therapy.","volume":"19","author":"Propper","year":"2022","journal-title":"Nat Rev Clin Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1093\/cvr\/cvz058","article-title":"Inflammation: a common contributor to cancer, aging, and cardiovascular diseases-expanding the concept of cardio-oncology.","volume":"115","author":"Libby","year":"2019","journal-title":"Cardiovasc Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.1093\/eurheartj\/ehx723","article-title":"Canakinumab for residual inflammatory risk.","volume":"38","author":"Ridker","year":"2017","journal-title":"Eur Heart J."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.817119","article-title":"Additional use of prostacyclin analogs in patients with pulmonary arterial hypertension: a meta-analysis.","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1155\/2008\/156875","article-title":"Activation and molecular targets of peroxisome proliferator-activated receptor-gamma ligands in lung cancer.","volume":"2008","author":"Nemenoff","year":"2008","journal-title":"PPAR Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1158\/1541-7786.MCR-09-0511","article-title":"Prostaglandin E2 promotes lung cancer cell migration via EP4-betaArrestin1-c-Src signalsome.","volume":"8","author":"Kim","year":"2010","journal-title":"Mol Cancer Res."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201708536","article-title":"Inflammation leads through PGE\/EP3 signaling to HDAC5\/MEF2-dependent transcription in cardiac myocytes.","volume":"10","author":"Toth","year":"2018","journal-title":"EMBO Mol Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1161\/CIRCULATIONAHA.117.030816","article-title":"Heart failure stimulates tumor growth by circulating factors.","volume":"138","author":"Meijers","year":"2018","journal-title":"Circulation."},{"key":"B35","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41568-021-00378-6","article-title":"Cancer metabolism: looking forward.","volume":"21","author":"Martinez-Reyes","year":"2021","journal-title":"Nat Rev Cancer."},{"key":"B36","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s11886-022-01650-3","article-title":"Strategies for imaging metabolic remodeling of the heart in obesity and heart failure.","volume":"24","author":"Haidar","year":"2022","journal-title":"Curr Cardiol Rep."},{"key":"B37","doi-asserted-by":"publisher","first-page":"14087","DOI":"10.1073\/pnas.1211502109","article-title":"Spectrum of somatic mitochondrial mutations in five cancers.","volume":"109","author":"Larman","year":"2012","journal-title":"Proc Natl Acad Sci USA."},{"key":"B38","doi-asserted-by":"publisher","first-page":"H742","DOI":"10.1152\/ajpheart.1994.267.2.H742","article-title":"Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts.","volume":"267","author":"Allard","year":"1994","journal-title":"Am J Physiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"10436","DOI":"10.1073\/pnas.1601650113","article-title":"Oncometabolite d-2-hydroxyglutarate impairs alpha-ketoglutarate dehydrogenase and contractile function in rodent heart.","volume":"113","author":"Karlstaedt","year":"2016","journal-title":"Proc Natl Acad Sci USA."},{"key":"B40","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.cell.2015.07.017","article-title":"Supporting aspartate biosynthesis is an essential function of respiration in proliferating cells.","volume":"162","author":"Sullivan","year":"2015","journal-title":"Cell."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1093\/cvr\/cvy063","article-title":"Glucose is preferentially utilized for biomass synthesis in pressure-overloaded hearts: evidence from fatty acid-binding protein-4 and -5 knockout mice.","volume":"114","author":"Umbarawan","year":"2018","journal-title":"Cardiovasc Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nrd3504","article-title":"Targeting cancer metabolism: a therapeutic window opens.","volume":"10","author":"Vander Heiden","year":"2011","journal-title":"Nat Rev Drug Discov."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2012.12.019","article-title":"The new cardiac metabolism.","volume":"55","author":"Taegtmeyer","year":"2013","journal-title":"J Mol Cell Cardiol."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.810791","article-title":"Sodium-glucose cotransporter 2 inhibitors and heart failure: a bedside-to-bench journey.","volume":"8","author":"Cappetta","year":"2021","journal-title":"Front Cardiovasc Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"E4111","DOI":"10.1073\/pnas.1511698112","article-title":"Functional expression of sodium-glucose transporters in cancer.","volume":"112","author":"Scafoglio","year":"2015","journal-title":"Proc Natl Acad Sci USA."},{"key":"B46","doi-asserted-by":"publisher","first-page":"24787","DOI":"10.18632\/oncotarget.25361","article-title":"Preclinical evaluation of novel fatty acid synthase inhibitors in primary colorectal cancer cells and a patient-derived xenograft model of colorectal cancer.","volume":"9","author":"Zaytseva","year":"2018","journal-title":"Oncotarget."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-30616-1","article-title":"Myocardial fatty acid uptake through CD36 is indispensable for sufficient bioenergetic metabolism to prevent progression of pressure overload-induced heart failure.","volume":"8","author":"Umbarawan","year":"2018","journal-title":"Sci Rep."},{"key":"B48","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2015.07.016","article-title":"An essential role of the mitochondrial electron transport chain in cell proliferation is to enable aspartate synthesis.","volume":"162","author":"Birsoy","year":"2015","journal-title":"Cell."},{"key":"B49","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.cmet.2016.09.006","article-title":"Environment dictates dependence on mitochondrial complex I for NAD+ and aspartate production and determines cancer cell sensitivity to metformin.","volume":"24","author":"Gui","year":"2016","journal-title":"Cell Metab."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.62644","article-title":"Glutamine deprivation triggers NAGK-dependent hexosamine salvage.","volume":"10","author":"Campbell","year":"2021","journal-title":"Elife."},{"key":"B51","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.jacc.2021.12.019","article-title":"Autophagy and reverse remodeling: a new biomarker in heart failure?","volume":"79","author":"Jefferies","year":"2022","journal-title":"J Am Coll Cardiol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.addr.2011.01.003","article-title":"Regulatory systems for hypoxia-inducible gene expression in ischemic heart disease gene therapy.","volume":"63","author":"Kim","year":"2011","journal-title":"Adv Drug Deliv Rev."},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/febs.16110","article-title":"Regulation of redox signaling in HIF-1-dependent tumor angiogenesis.","author":"Manuelli","year":"2021","journal-title":"FEBS J."},{"key":"B54","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/MOH.0000000000000138","article-title":"Endothelial cells and cancer cells: metabolic partners in crime?","volume":"22","author":"Zecchin","year":"2015","journal-title":"Curr Opin Hematol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1172\/JCI24682","article-title":"Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure.","volume":"115","author":"Shiojima","year":"2005","journal-title":"J Clin Invest."},{"key":"B56","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1071\/RD12139","article-title":"The role of hypoxia-induced genes in ovarian angiogenesis.","volume":"25","author":"Meidan","year":"2013","journal-title":"Reprod Fertil Dev."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20092067","article-title":"Alternative splicing in angiogenesis.","volume":"20","author":"Bowler","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B58","doi-asserted-by":"publisher","first-page":"H844","DOI":"10.1152\/ajpheart.00898.2009","article-title":"Divergent roles of prokineticin receptors in the endothelial cells: angiogenesis and fenestration.","volume":"298","author":"Guilini","year":"2010","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1073\/pnas.0337667100","article-title":"The endocrine-gland-derived VEGF homologue Bv8 promotes angiogenesis in the testis: localization of Bv8 receptors to endothelial cells.","volume":"100","author":"LeCouter","year":"2003","journal-title":"Proc Natl Acad Sci USA."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s11936-014-0335-0","article-title":"Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway.","volume":"16","author":"Groarke","year":"2014","journal-title":"Curr Treat Options Cardiovasc Med."},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.694711","article-title":"Updates on anticancer therapy-mediated vascular toxicity and new horizons in therapeutic strategies.","volume":"8","author":"Hsu","year":"2021","journal-title":"Front Cardiovasc Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jacc.2019.06.007","article-title":"Clonal hematopoiesis: crossroads of aging, cardiovascular disease, and cancer: JACC review topic of the week.","volume":"74","author":"Libby","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3791\/59977","article-title":"Lentiviral CRISPR\/Cas9-mediated genome editing for the study of hematopoietic cells in disease models.","volume":"2019","author":"Sano","year":"2019","journal-title":"J Vis Exp."},{"key":"B64","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ajhg.2017.05.013","article-title":"Ultra-sensitive sequencing identifies high prevalence of clonal hematopoiesis-associated mutations throughout adult life.","volume":"101","author":"Acuna-Hidalgo","year":"2017","journal-title":"Am J Hum Genet."},{"key":"B65","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ajh.26455","article-title":"Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management.","volume":"97","author":"Patnaik","year":"2022","journal-title":"Am J Hematol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41569-019-0247-5","article-title":"Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease.","volume":"17","author":"Jaiswal","year":"2020","journal-title":"Nat Rev Cardiol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.3324\/haematol.2019.224402","article-title":"Hematopoietic alterations in chronic heart failure patients by somatic mutations leading to clonal hematopoiesis.","volume":"105","author":"Dorsheimer","year":"2020","journal-title":"Haematologica."},{"key":"B68","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/jamacardio.2018.3965","article-title":"Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure.","volume":"4","author":"Dorsheimer","year":"2019","journal-title":"JAMA Cardiol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1001\/jamacardio.2019.0302","article-title":"Connections between clonal hematopoiesis, cardiovascular disease, and cancer: a review.","volume":"4","author":"Calvillo-Arguelles","year":"2019","journal-title":"JAMA Cardiol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.2459\/JCM.0000000000000459","article-title":"The natural history of dilated cardiomyopathy: how has it changed?","volume":"18","author":"Merlo","year":"2017","journal-title":"J Cardiovasc Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.hfc.2017.12.007","article-title":"Epidemiology and clinical aspects of genetic cardiomyopathies.","volume":"14","author":"Masarone","year":"2018","journal-title":"Heart Fail Clin."},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2014-000116","article-title":"Potential genetic predisposition for anthracycline-associated cardiomyopathy in families with dilated cardiomyopathy.","volume":"1","author":"Wasielewski","year":"2014","journal-title":"Open Heart."},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9061702","article-title":"Genetic factors involved in cardiomyopathies and in cancer.","volume":"9","author":"Sabater-Molina","year":"2020","journal-title":"J Clin Med."},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1186\/s40659-021-00342-6","article-title":"Molecules linked to Ras signaling as therapeutic targets in cardiac pathologies.","volume":"54","author":"Ramos-Kuri","year":"2021","journal-title":"Biol Res."},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.049107","article-title":"The RASopathies: from pathogenetics to therapeutics.","volume":"15","author":"Hebron","year":"2022","journal-title":"Dis Model Mech."},{"key":"B76","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41569-019-0200-7","article-title":"Molecular mechanisms of arrhythmogenic cardiomyopathy.","volume":"16","author":"Austin","year":"2019","journal-title":"Nat Rev Cardiol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s11906-012-0290-7","article-title":"Blood pressure variability, cardiovascular risk, and risk for renal disease progression.","volume":"14","author":"Parati","year":"2012","journal-title":"Curr Hypertens Rep."},{"key":"B78","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrc3978","article-title":"Sympathetic nervous system regulation of the tumour microenvironment.","volume":"15","author":"Cole","year":"2015","journal-title":"Nat Rev Cancer."},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4209","article-title":"Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study.","volume":"363","author":"Hicks","year":"2018","journal-title":"BMJ."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1161\/CIRCULATIONAHA.110.007336","article-title":"Use of angiotensin receptor blockers and the risk of cancer.","volume":"123","author":"Pasternak","year":"2011","journal-title":"Circulation."},{"key":"B81","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/jch.14187","article-title":"Effect of angiotensin receptor blockers on the development of cancer: a nationwide cohort study in korea.","volume":"23","author":"Jung","year":"2021","journal-title":"J Clin Hypertens."},{"key":"B82","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.jaad.2017.11.042","article-title":"Hydrochlorothiazide use and risk of nonmelanoma skin cancer: a nationwide case-control study from Denmark.","volume":"78","author":"Pedersen","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S1470-2045(10)70106-6","article-title":"Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials.","volume":"11","author":"Sipahi","year":"2010","journal-title":"Lancet Oncol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1200\/JCO.2011.35.1908","article-title":"Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study.","volume":"29","author":"Chang","year":"2011","journal-title":"J Clin Oncol."},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0263461","article-title":"Risk of cancer with angiotensin-receptor blockers increases with increasing cumulative exposure: meta-regression analysis of randomized trials.","volume":"17","author":"Sipahi","year":"2022","journal-title":"PLoS One."},{"key":"B86","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s11912-013-0351-3","article-title":"Role of aspirin in cancer prevention.","volume":"15","author":"Thorat","year":"2013","journal-title":"Curr Oncol Rep."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","article-title":"Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.","volume":"392","author":"Gaziano","year":"2018","journal-title":"Lancet."},{"key":"B88","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0140-6736(18)31133-4","article-title":"Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials.","volume":"392","author":"Rothwell","year":"2018","journal-title":"Lancet."},{"key":"B89","doi-asserted-by":"publisher","first-page":"836","DOI":"10.7326\/M16-0577","article-title":"Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement.","volume":"164","author":"Bibbins-Domingo","year":"2016","journal-title":"Ann Intern Med."},{"key":"B90","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10557-021-07145-7","article-title":"Aspirin alone versus dual antiplatelet therapy after transcatheter aortic valve replacement: a systematic review and meta-analysis.","volume":"36","author":"Lin","year":"2021","journal-title":"Cardiovasc Drugs Ther."},{"key":"B91","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00520-007-0367-z","article-title":"Biomarkers for cancer cachexia: is there also a genetic component to cachexia?","volume":"16","author":"Tan","year":"2008","journal-title":"Support Care Cancer."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1038\/s41430-018-0245-4","article-title":"Cancer-associated malnutrition.","volume":"72","author":"Baracos","year":"2018","journal-title":"Eur J Clin Nutr."},{"key":"B93","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1152\/physrev.00016.2008","article-title":"Mechanisms of cancer cachexia.","volume":"89","author":"Tisdale","year":"2009","journal-title":"Physiol Rev."},{"key":"B94","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/00075197-200207000-00009","article-title":"Biochemical mechanisms of cellular catabolism.","volume":"5","author":"Tisdale","year":"2002","journal-title":"Curr Opin Clin Nutr Metab Care."},{"key":"B95","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/978-981-10-6020-5_11","article-title":"Metabolic changes during cancer cachexia pathogenesis.","volume":"1026","author":"Shyh-Chang","year":"2017","journal-title":"Adv Exp Med Biol."},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0236680","article-title":"Withaferin A attenuates ovarian cancer-induced cardiac cachexia.","volume":"15","author":"Kelm","year":"2020","journal-title":"PLoS One."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1002\/jcsm.12451","article-title":"Rapid atrophy of cardiac left ventricular mass in patients with non-small cell carcinoma of the lung.","volume":"10","author":"Kazemi-Bajestani","year":"2019","journal-title":"J Cachexia Sarcopenia Muscle."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1158\/0008-5472.CAN-10-3145","article-title":"Cancer causes cardiac atrophy and autophagy in a sexually dimorphic manner.","volume":"71","author":"Cosper","year":"2011","journal-title":"Cancer Res."},{"key":"B99","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/j.1365-2362.2008.01970.x","article-title":"Muscle myostatin signalling is enhanced in experimental cancer cachexia.","volume":"38","author":"Costelli","year":"2008","journal-title":"Eur J Clin Invest."},{"key":"B100","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1093\/eurheartj\/eht302","article-title":"Prevention of liver cancer cachexia-induced cardiac wasting and heart failure.","volume":"35","author":"Springer","year":"2014","journal-title":"Eur Heart J."},{"key":"B101","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1161\/STROKEAHA.114.006258","article-title":"Catabolic signaling and muscle wasting after acute ischemic stroke in mice: indication for a stroke-specific sarcopenia.","volume":"45","author":"Springer","year":"2014","journal-title":"Stroke."},{"key":"B102","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s13539-014-0153-y","article-title":"Formoterol in the treatment of experimental cancer cachexia: effects on heart function.","volume":"5","author":"Toledo","year":"2014","journal-title":"J Cachexia Sarcopenia Muscle."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s00520-013-2081-3","article-title":"Phase I\/II trial of formoterol fumarate combined with megestrol acetate in cachectic patients with advanced malignancy.","volume":"22","author":"Greig","year":"2014","journal-title":"Support Care Cancer."},{"key":"B104","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1172\/JCI117929","article-title":"Muscle protein waste in tumor-bearing rats is effectively antagonized by a beta 2-adrenergic agonist (clenbuterol). Role of the ATP-ubiquitin-dependent proteolytic pathway.","volume":"95","author":"Costelli","year":"1995","journal-title":"J Clin Invest."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1006\/cyto.2002.1036","article-title":"Anticytokine treatment prevents the increase in the activity of ATP-ubiquitin- and Ca(2+)-dependent proteolytic systems in the muscle of tumour-bearing rats.","volume":"19","author":"Costelli","year":"2002","journal-title":"Cytokine."},{"key":"B106","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.cell.2010.07.011","article-title":"Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival.","volume":"142","author":"Zhou","year":"2010","journal-title":"Cell."},{"key":"B107","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrclinonc.2018.14","article-title":"Bridging the gap: are animal models consistent with clinical cancer cachexia?","volume":"15","author":"Baracos","year":"2018","journal-title":"Nat Rev Clin Oncol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.molmet.2015.11.004","article-title":"Ataxin-10 is part of a cachexokine cocktail triggering cardiac metabolic dysfunction in cancer cachexia.","volume":"5","author":"Schafer","year":"2016","journal-title":"Mol Metab."},{"key":"B109","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1101\/gad.231233.113","article-title":"D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice.","volume":"28","author":"Akbay","year":"2014","journal-title":"Genes Dev."},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3390\/ph14100970","article-title":"Anticancer drug-induced cardiotoxicity: insights and pharmacogenetics.","volume":"14","author":"Adhikari","year":"2021","journal-title":"Pharmaceuticals."},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01262","article-title":"Updates in anthracycline-mediated cardiotoxicity.","volume":"9","author":"Nebigil","year":"2018","journal-title":"Front Pharmacol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.tips.2015.03.005","article-title":"Anthracyclines\/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms.","volume":"36","author":"Rochette","year":"2015","journal-title":"Trends Pharmacol Sci."},{"key":"B113","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1161\/HYPERTENSIONAHA.117.08856","article-title":"Recent advances in hypertension and cardiovascular toxicities with vascular endothelial growth factor inhibition.","volume":"70","author":"Touyz","year":"2017","journal-title":"Hypertension."},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000247","article-title":"Cardiotoxicity of immune checkpoint inhibitors.","volume":"2","author":"Varricchi","year":"2017","journal-title":"ESMO Open."},{"key":"B115","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1161\/CIRCULATIONAHA.118.033907","article-title":"Heart disease and cancer: are the two killers colluding?","volume":"138","author":"Kitsis","year":"2018","journal-title":"Circulation."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/s41591-020-0964-7","article-title":"Myocardial infarction accelerates breast cancer via innate immune reprogramming.","volume":"26","author":"Koelwyn","year":"2020","journal-title":"Nat Med."},{"key":"B117","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1161\/CIRCULATIONAHA.120.046471","article-title":"Early cardiac remodeling promotes tumor growth and metastasis.","volume":"142","author":"Avraham","year":"2020","journal-title":"Circulation."},{"key":"B118","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jaccao.2022.01.100","article-title":"Incident cardiovascular disease among adults with cancer: a population-based cohort study.","volume":"4","author":"Paterson","year":"2022","journal-title":"JACC CardioOncol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1161\/CIRCRESAHA.116.309115","article-title":"Decline in cardiovascular mortality: possible causes and implications.","volume":"120","author":"Mensah","year":"2017","journal-title":"Circ Res."},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2022.100415","article-title":"Congenital heart disease and the risk of cancer: the importance of understanding associated comorbidities.","volume":"18","author":"Mejia","year":"2022","journal-title":"Lancet Reg Health Eur."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.929259\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T05:29:41Z","timestamp":1657862981000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.929259\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,15]]},"references-count":120,"alternative-id":["10.3389\/fcvm.2022.929259"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.929259","relation":{},"ISSN":["2297-055X"],"issn-type":[{"type":"electronic","value":"2297-055X"}],"subject":[],"published":{"date-parts":[[2022,7,15]]},"article-number":"929259"}}